Publication Name	World Journal of Pharmacology
Manuscript ID	31093
Country	United Kingdom

Received	2016-10-30 13:37
Peer-Review Started	2016-11-02 11:54
To Make the First Decision	2016-12-01 14:34
Return for Revision	2016-12-05 13:39
Revised	2017-01-06 04:15
Second Decision	2017-01-18 13:30
Accepted by Journal Editor-in-Chief	2017-01-19 17:37
Accepted by Company Editor-in-Chief	2017-02-13 11:09
Articles in Press	2017-02-13 11:10
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2017-02-27 13:44
Publish the Manuscript Online	2017-03-02 10:37

ISSN	2220-3192 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Pharmacology & Pharmacy
Manuscript Type	Minireviews
Article Title	Emerging pharmacological strategies for the treatment of fibromyalgia
Manuscript Source	Invited Manuscript
All Author List	Kim Lawson
Funding Agency and Grant Number
Corresponding Author	Kim Lawson, BTech(Hons), PhD, Senior Lecturer, Department of Biosciences and Chemistry, Biomolecular Sciences Research Centre, Sheffield Hallam University, City Campus, Sheffield S1 1WB, United Kingdom. k.lawson@shu.ac.uk
Key Words	Fibromyalgia; Chronic pain; Fatigue; Central sensitization; NMDA receptors; Melatonin receptors; Gabapentanoids
Core Tip	Fibromyalgia (FM) is a multidimensional chronic pain condition that current therapies provide modest and limited efficacy due to the heterogeneity of the condition, contribution of peripheral and central components to the pathophysiology, and a range of co-morbidities. Drugs acting on novel and existing targets, such as melatoninergic, cannabinoid, dopamine, NMDA, angiotensin, orexin and opioid receptors, ion channels, bioamine processes and subunits have provided efficacy outcomes that improve the health status of patients with FM. An understanding of the pathophysiology of FM is providing potential targets for new medications.
Publish Date	2017-03-02 10:37
Citation	Lawson K. Emerging pharmacological strategies for the treatment of fibromyalgia. World J Pharmacol 2017; 6(1): 1-10
URL	http://www.wjgnet.com/2220-3192/full/v6/i1/1.htm
DOI	http://dx.doi.org/10.5497/wjp.v6.i1.1

Full Article (PDF)	WJP-6-1.pdf
Full Article (Word)	WJP-6-1.doc
Manuscript File	31093-Review.docx
Answering Reviewers	31093-Answering reviewers.pdf
Audio Core Tip	31093-Audio core tip.wav
Conflict-of-Interest Disclosure Form	31093-Conflict-of-interest statement.pdf
Copyright License Agreement	31093-Copyright assignment.pdf
Peer-review Report	31093-Peer-review(s).pdf
Journal Editor-in-Chief Review Report	31093-Journal editor-in-chief review report.pdf
Scientific Misconduct Check	31093-Scientific misconduct check.pdf
Scientific Editor Work List	31093-Scientific editor work list.pdf